Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Research dashboard

Search approved medicines for AI-predicted activity against four drug-resistant pathogens, and see what evidence is already documented for each one.

TryTuberculosisMRSAKlebsiella infectionE. coli infection

1,761

Approved medicines

Approved medicines matched to the FDA Orange Book, antimicrobials included

1,276

Medicines with ≥40% AI-predicted activity

Against at least one of the four supported pathogens; each medicine counted once

1,019

Repurposing candidates

Of those, the medicines that are not already antimicrobials

How the repurposing candidates are counted

  1. 1,761approved medicines

  2. 1,276with AI-predicted activity ≥40% against at least one pathogen

    − 485 below ≥40%, not counted

  3. 1,120not already antimicrobials

    − 156 already antimicrobials, set aside

  4. 1,019repurposing candidates

    − 101 needing review, kept in the library

Existing antimicrobials are identified from WHO ATC codes and FDA pharmacologic classes. Medicines needing review (neither source says whether they are antimicrobials) stay in the approved-medicine download, marked “unclassified”. They are not assumed to be non-antimicrobials, so they are not counted as candidates.

Downloads

Download approved medicines (CSV)1,761 rowsDownload repurposing candidates (CSV)1,019 rows

Pathogen coverage

A medicine can count under more than one

Registered studies

A registration describes a study; it does not establish a positive result.

Condition
When these studies started38,873 of 39,548 have a start date · most in 2021 (1,903)
193119812030

  • Role of Omega-DEK in Childhood Apraxia of Speech

    NCT07216001 · start 2026-11

    Registered record
    Registry ID
    NCT07216001
    Conditions
    Childhood Apraxia of Speech; Verbal Apraxia; Autism
    Interventions
    Omega-DEK; L-carnitine; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-11
    Completion
    2027-12
    Enrolment
    34

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChildhood Apraxia of Speech; Verbal Apraxia; Autism
    InterventionOmega-DEK; L-carnitine; Placebo
    PhasePhase 2
    Registry statusNot yet recruiting

  • Remote Interventions for Menthol Cigarette Use

    NCT07356297 · start 2026-11

    Registered record
    Registry ID
    NCT07356297
    Conditions
    Cigarette Smoking
    Interventions
    Quitline (QL); Mobile incentive-based intervention
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2026-11
    Completion
    2030-04
    Enrolment
    1,200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCigarette Smoking
    InterventionQuitline (QL); Mobile incentive-based intervention
    PhaseNot applicable
    Registry statusNot yet recruiting

  • T4/T3 Therapy in Hypothyroidism

    NCT07424183 · start 2026-11

    Registered record
    Registry ID
    NCT07424183
    Conditions
    Hypothyroidism Primary
    Interventions
    Liothyronine (L-T3); Levothyroxine Sodium (LT4) Tablets; Liothyronine (LT3) placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-11
    Completion
    2027-11
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypothyroidism Primary
    InterventionLiothyronine (L-T3); Levothyroxine Sodium (LT4) Tablets; Liothyronine (LT3) placebo
    PhasePhase 2
    Registry statusNot yet recruiting

  • Comparing Momelotinib and Ruxolitinib in People With Untreated Myelofibrosis and Low Blood Cell Counts

    NCT07498205 · start 2026-11

    Registered record
    Registry ID
    NCT07498205
    Conditions
    Myelofibrosis; Myelofibrosis (MF)
    Interventions
    Momelotinib; Ruxolitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2026-11
    Completion
    2031-08-08
    Enrolment
    268

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMyelofibrosis; Myelofibrosis (MF)
    InterventionMomelotinib; Ruxolitinib
    PhasePhase 4
    Registry statusNot yet recruiting

  • Lurbinectedin Plus Paclitaxel Versus Paclitaxel in Patients With Previously Treated Small Cell Lung Cancer

    NCT07640932 · start 2026-11

    Registered record
    Registry ID
    NCT07640932
    Conditions
    Carcinoma, Small Cell Lung
    Interventions
    Lurbinectedin; Paclitaxel
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-11
    Completion
    2029-02
    Enrolment
    69

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarcinoma, Small Cell Lung
    InterventionLurbinectedin; Paclitaxel
    PhasePhase 2
    Registry statusNot yet recruiting

  • Haloperidol For Outpatient Symptom Management in Patients Diagnosed With Cannabinoid Hyperemesis Syndrome in the Emergrency Department

    NCT07726069 · start 2026-11

    Registered record
    Registry ID
    NCT07726069
    Conditions
    Cannabinoid Hyperemesis Syndrome
    Interventions
    Haloperidol
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Not yet recruiting
    Start
    2026-11
    Completion
    2028-01
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCannabinoid Hyperemesis Syndrome
    InterventionHaloperidol
    PhaseEarly phase 1
    Registry statusNot yet recruiting

  • Hormone thERapy Effects on BRAin-HEART Health During the Menopausal Transition

    NCT07732452 · start 2026-11

    Registered record
    Registry ID
    NCT07732452
    Conditions
    Menopause; Perimenopause; Vasomotor Symptoms; Cardiovascular Disease Risk Factor; Menopausal Hormone Therapy; Cardiac Remodeling; Myocardial Fibrosis; Microvascular Dysfunction; Cognitive Function Assessment
    Interventions
    Transdermal estradiol; Standard of care - non hormonal
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2026-11
    Completion
    2029-01
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMenopause; Perimenopause; Vasomotor Symptoms; Cardiovascular Disease Risk Factor +5 more
    InterventionTransdermal estradiol; Standard of care - non hormonal
    PhasePhase 4
    Registry statusNot yet recruiting

  • Different Treatment Frequencies for Hepatic Fibrosis Due to Schistosomiasis

    NCT07754617 · start 2026-11

    Registered record
    Registry ID
    NCT07754617
    Conditions
    Schistosomiasis; Schistosoma Mansoni; Liver Fibrosis; Portal Hypertension
    Interventions
    Praziquantel 40 mg/kg per dose given once annually; Praziquantel 40 mg/kg given three times per year
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Not yet recruiting
    Start
    2026-11
    Completion
    2029-11
    Enrolment
    600

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchistosomiasis; Schistosoma Mansoni; Liver Fibrosis; Portal Hypertension
    InterventionPraziquantel 40 mg/kg per dose given once annually; Praziquantel 40 mg/kg given three times per year
    PhasePhase 2 / Phase 3
    Registry statusNot yet recruiting

  • Needlefree Lidocaine Application for Vulvar Biopsies

    NCT07793552 · start 2026-11

    Registered record
    Registry ID
    NCT07793552
    Conditions
    Vulvar Cancers; Vulva Neoplasm; Vulvar Dysplasia
    Interventions
    J-Tip; Lidocaine HCl 1%
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2026-11
    Completion
    2030-11
    Enrolment
    106

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVulvar Cancers; Vulva Neoplasm; Vulvar Dysplasia
    InterventionJ-Tip; Lidocaine HCl 1%
    PhaseNot applicable
    Registry statusNot yet recruiting

  • Lemborexant for Cannabis Use Disorder

    NCT07802990 · start 2026-11

    Registered record
    Registry ID
    NCT07802990
    Conditions
    Cannabis Use Disorder
    Interventions
    Lemborexant 10mg; Placebo; Brief Behavioural Intervention
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-11
    Completion
    2028-11
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCannabis Use Disorder
    InterventionLemborexant 10mg; Placebo; Brief Behavioural Intervention
    PhasePhase 1 / Phase 2
    Registry statusNot yet recruiting

  • Resistance-Optimised Antimicrobial Dosing in Critically Ill Patients, a Randomised Controlled Trial

    NCT07820501 · start 2026-11

    Registered record
    Registry ID
    NCT07820501
    Conditions
    Hospital-acquired Pneumonia (HAP); Ventilator-Associated Pneumonia (VAP); Nosocomial Respiratory Infection; Critical Illness
    Interventions
    Resistance-Optimised Precision Dosing; Standard Care Dosing
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2026-11
    Completion
    2029-09
    Enrolment
    610

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHospital-acquired Pneumonia (HAP); Ventilator-Associated Pneumonia (VAP); Nosocomial Respiratory Infection; Critical Illness
    InterventionResistance-Optimised Precision Dosing; Standard Care Dosing
    PhaseNot applicable
    Registry statusNot yet recruiting

  • A Study of Selpercatinib (LY3527723) in Participants With Rearranged During Transfection (RET)-Altered Cancers in India

    NCT07822880 · start 2026-11

    Registered record
    Registry ID
    NCT07822880
    Conditions
    Thyroid Neoplasms; Carcinoma, Non-Small-Cell Lung
    Interventions
    Selpercatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2026-11
    Completion
    2029-10
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionThyroid Neoplasms; Carcinoma, Non-Small-Cell Lung
    InterventionSelpercatinib
    PhasePhase 4
    Registry statusNot yet recruiting

  • Serratus Plane Block (SPB) Versus Capsaïcine Versus Botox-A for Chronic Neuropathic Pain in Post-mastectomy Syndrome

    NCT06807164 · start 2026-10-31

    Registered record
    Registry ID
    NCT06807164
    Conditions
    Post-Mastectomy Neuropathic Pain Syndrome
    Interventions
    Capsaicin 8% Patch; Serratus Plane Block; Botulinum Toxin A
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2026-10-31
    Completion
    2027-12-30
    Enrolment
    123

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPost-Mastectomy Neuropathic Pain Syndrome
    InterventionCapsaicin 8% Patch; Serratus Plane Block; Botulinum Toxin A
    PhasePhase 2
    Registry statusRecruiting

  • Safety and Efficacy of Radiotherapy Combined With Immunochemotherapy in Pre-treated SCLC Patients With Liver Metastases

    NCT07258147 · start 2026-10-31

    Registered record
    Registry ID
    NCT07258147
    Conditions
    Lung Cancer (SCLC)
    Interventions
    Immunotherapy; Chemotherapy (Etoposide, Nab-paclitaxel, Irinotecan, or Lurbinectedin); low-dose radiation; Stereotactic Body Radiation Therapy (SBRT)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-10-31
    Completion
    2028-12-30
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLung Cancer (SCLC)
    InterventionImmunotherapy; Chemotherapy (Etoposide, Nab-paclitaxel, Irinotecan, or Lurbinectedin); low-dose radiation; Stereotactic Body Radiation Therapy (SBRT)
    PhasePhase 2
    Registry statusNot yet recruiting

  • Fluorometholone Study

    NCT07308938 · start 2026-10-31

    Registered record
    Registry ID
    NCT07308938
    Conditions
    Keratitis Bacterial; Corneal Ulcer (Diagnosis)
    Interventions
    Adjunctive Topical Fluorometholone (FML) 0.1%; Standard Topical Antibiotic Therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-10-31
    Completion
    2030-12-31
    Enrolment
    174

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionKeratitis Bacterial; Corneal Ulcer (Diagnosis)
    InterventionAdjunctive Topical Fluorometholone (FML) 0.1%; Standard Topical Antibiotic Therapy
    PhasePhase 2
    Registry statusNot yet recruiting

AI-predicted activity is a model’s estimate that a molecule is active against a pathogen in the laboratory. It is not clinical effectiveness. The models describe each pathogen species; the data behind them rarely records resistant strains.